Drug intelligence / Profile preview

33BBzT2

Development stage: Preclinical
Lead developer: Wellington Zhaotai Therapies
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

33BBzT2 is a preclinical chimeric antigen receptor (CAR) T-cell therapy developed by Wellington Zhaotai. It is engineered to target CD33, a transmembrane protein frequently expressed on the surface of myeloid cells and in hematologic malignancies such as Acute Myeloid Leukaemia (AML). The construct features a 4-1BB (CD137) co-stimulatory domain, which is designed to enhance the metabolic profile, persistence, and anti-tumor efficacy of the CAR T cells compared to first-generation or CD28-based constructs. The therapy is currently being investigated for its potential in treating Multiple Myeloma and Acute Myeloid Leukaemia.

Other names: CD33-CAR-T (4-1BB)

Targets

CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on 33BBzT2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 33BBzT2.

Explore the full profile